Navigation Links
Where do you start when developing a new medicine?
Date:3/26/2014

ch of the three founding organisations and a multi-million pound contribution by GSK to fund an initial wave of projects.

Comments by the founding organisations:

Professor Patrick Vallance, President of Pharmaceuticals R&D at GSK, says: "Target validation is one of the greatest challenges in drug discovery. We need to understand better the mechanisms in our body related to disease to improve how we can develop the most effective medicines. By changing our business model, taking a more open-minded approach to sharing information and forging collaborations like the Centre for Therapeutic Target Validation, we believe there is an opportunity to accelerate the development of innovative new medicines. The UK leads the fields of genome sequencing and bioinformatics and I am delighted that GSK has the opportunity to collaborate here with two of its premier research institutions."

Professor Sir Mike Stratton, Director of the Wellcome Trust Sanger Institute, says: "Advances in genomics have led to a rapid increase in the availability of drug targets, providing enormous opportunity but also posing the problem of how we best convert this new knowledge into medicines. The challenge we now address is to identify those new targets with the greatest relevance to human disease which, in turn, will undoubtedly increase the speed and efficiency in which new medicines can be developed."

Professor Dame Janet Thornton, Director of the European Bioinformatics Institute, says: "Maximising our use of 'big data' in the life sciences is critical for solving some of society's most pressing problems. This collaboration gives us an opportunity to translate this complex information into biomedical discoveries. As biology becomes increasingly data-driven, pre-competitive collaborations such as the Centre for Therapeutic Target Validation have become crucial for improving efficiencies, driving down costs and providing the best opportunities to
'/>"/>

Contact: EMBL Press Office
pressoffice@embl.de
44-078-813-77941
European Molecular Biology Laboratory
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Targeting enforcement where needed most in Africas heart of biodiversity
2. Where have all the codfish gone?
3. Dating is refined for the Atapuerca site where Homo antecessor appeared
4. Where do lizards in Qatar live? First distribution maps for the state
5. Tiny swimming bio-bots boldly go where no bot has swum before
6. Study shows Where Alzheimers starts and how it spreads
7. Big data project reveals where carbon-stocking projects in Africa provide the greatest benefits
8. High-resolution 3-D imaging draws new picture of Golgis whereabouts during cell division
9. Where water is limited, researchers determine how much water is enough
10. 2-way traffic enable proteins to get where needed, avoid disease
11. Deletion of any single gene provokes mutations elsewhere in the genome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Where do you start when developing a new medicine?
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... These Bluefin Are Skinny DURHAM, N.H. The ... of Maine has declined significantly since the early 1990s, ... by analyzing detailed logbooks from a commercial tuna grader ... week in Fishery Bulletin, indicate potential changes in food ...
... tumor therapy has shown promising tumor cell selectivity in ... Nottingham scientists. The project, conducted jointly in the Schools ... featured in the September issue of the Experimental Biology ... for a number of reasons, including getting sufficient drug ...
... MADISON, WI, AUGUST 22, 2007- Climate change, a recent ... surface; however, the study of another important factor to ... scientists are looking deep enough to see the possible ... known about how soil, subsurface waters, and groundwater are ...
Cached Biology News:Condition of bluefin tuna in gulf of maine is declining 2Condition of bluefin tuna in gulf of maine is declining 3Novel 3-D cell culture model shows selective tumor uptake of nanoparticles 2Climate change goes underground 2Climate change goes underground 3
(Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... that Dr. Robert Harman, DVM, MPVM, CEO of Vet-Stem, ... of Action" at the Annual Research Symposium of the ... October 21, 2010.   (Logo: http://photos.prnewswire.com/prnh/20060425/VETSTEMLOGO ... Dr. Harman has presented at more than 40 veterinary ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, ... for its CYT387 JAK1/JAK2 inhibitor program demonstrating that ... profile which may provide significant clinical advantages. CYT387 ... clinical study at Mayo Clinic in patients with ...
... RALEIGH, NC and QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ ... of Medicago Inc. (TSX: MDG), a biotechnology company ... based on proprietary manufacturing technologies and Virus-Like Particles ... U.S. Senator Kay Hagan (D-NC) and U.S. Congressman ...
Cached Biology Technology:Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 3Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3
...
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... deparaffinize and perform Heat Induced Antigen Retrieval ... mounted on glass microscope slides. Deparffinization is ... high temperature used in HIER (over 90degrees ... by detergent. Formaldehyde fixation impairs or totally ...
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
Biology Products: